|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 1 September 2006, Vol. 108, No. 5, pp. 1778.
CORRESPONDENCE To the editor:False-positive Epo test concerns unfoundedThe brief report by Beullens et al1 is misleading regarding the urine test that the World Anti-Doping Agency (WADA) uses to detect recombinant human erythropoietin (rhEpo). The WADA-recommended test is based on immunoelectorphoresis and double blotting (IEF/DB), and was developed by Lasne and de Ceaurriz in 2000.2Our WADA-accredited laboratory has performed the IEF/DB test for rhEpo on more than 6800 urine samples, including more than 2600 doping control samples from athletes. Of the latter, we have reported 9 positive cases for rhEpo: 3 of these have publicly confessed to using rhEpo, 3 have accepted penalties, the physician of a seventh has been indicted for distribution of rhEpo, and 2 maintained their innocence but lost on appeal. We take issue with Beullens's use of the term "false positive" because, as the authors emphasize, the compound they are discussing is not rhEpo. If the compound detected can be identified as not rhEpo, then it cannot cause a false positive. This term sensationalizes an otherwise interesting case report that could in due course contribute to the body of science. The criteria used by the WADA laboratories are well known and readily available.3 Beullens et al do not state the criteria they used to make the "false-positive" claim. Using the WADA criteria, the "false-positive" electropherogram1(Fig1A) is clearly negative. Moreover, they do not include a negative or a positive urine quality-control sample. Forensic testing results are normally accompanied by a comprehensive documentation package that supports the conclusion. A report such as this that raises a profound issue (false accusations against an athlete) at a minimum requires far more documentation.
Another important but unexplained issue is the nature of the compound that appears to migrate in the same general region as rhEpo and is characterized by bands. The pH range of the ampholytes is needed in order to fully interpret the data. In the left panel of their Figure 1A, the epoietin-
The right panel of their Figure 1A shows an apparent protein with bands, but it does not look like a typical rhEpo positive (Figure 1 here). Further, 1 and maybe 2 of the bands migrate more basically than the most basic epoietin-
Finally, the athlete has a puzzling renal disease characterized by a concentrating defect and an excessive number of casts that apparently does not interfere with his athletic prowess. He should have a full nephrology evaluation.
Correspondence: Don Catlin, Department of Molecular and Medical Pharmacology, UCLA Olympic Analytical Laboratory, University of California, Los Angeles, Los Angeles, CA 90025; e-mail: dcatlin{at}ucla.edu.
References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
lane shows 3 faint bands and possibly a very weak fourth band. The bands in the darbepoetin lane are overly dense. Knowing the pH range of the ampholytes might explain why the darbepoetin region seems closer to the rHuEPO region than we customarily observe (compare with 
